---
title: "Cancer type–specific chromatin regulator mutations linked to better survival after immune checkpoi"
id: "medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.15.26363151v1?rss=1"
published_at: "2026-09-16T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cancer type–specific chromatin regulator mutations linked to better survival after immune checkpoi
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.15.26363151v1?rss=1)
- **Published At:** 2026-09-16T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study analyzed mutations in **chromatin regulator (CR)** genes across multiple cancer types and their association with outcomes after immune checkpoint inhibitor (ICI) treatment. - Researchers used a discovery cohort and an independent validation cohort drawn from publicly available cancer genomics datasets to resolve associations at the level of individual cancer types. - Ten cancer types were specifically profiled: colorectal cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, bladder cancer, esophagogastric cancer, pancreatic adenocarcinoma, prostate cancer, and breast cancer. - For each cancer type the authors identified distinct sets of CR genes whose mutations were associated with **improved survival** after ICI therapy; these were termed pro-survival CR genes. - A subset of CR genes showed **recurrent** associations with improved ICI outcomes across multiple cancer types, although the strength of the association varied by cancer. - Co-occurrence of mutations in two or more CR genes correlated with further improvement in survival compared with single CR alterations. - CR-altered patient groups consistently displayed higher **tumor mutational burden (TMB)** than CR-unaltered groups across cancer types. - Transcriptomics-based deconvolution of the tumor microenvironment revealed **cancer-type-specific** differences in immune and stromal composition associated with CR mutations. - The results support a relationship among CR alterations, increased TMB, and better ICI response, highlighting both cancer-specific and shared mutation patterns; data sources and code are publicly available via cBioPortal resources. - The article is a preprint and has not been peer reviewed; the authors declared no competing interests and noted no dedicated external funding for the study.
## Clinical Analysis & Structured Key Points
Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy | medRxiv Skip to main content Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy Djansel Bukovec , Marija Gjorgjievska , Sara Kocevska , Mia Nikolova , Lina Mirkovikj , Ivan Kungulovski , Zan Mitrev , View ORCID Profile Goran Kungulovski doi: https://doi.org/10.64898/2026.09.15.26363151 Djansel Bukovec 1 Zan Mitrev Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marija Gjorgjievska 1 Zan Mitrev Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sara Kocevska 1 Zan Mitrev Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mia Nikolova 1 Zan Mitrev Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lina Mirkovikj 1 Zan Mitrev Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ivan Kungulovski 2 Fingerprint Diagnostics Find this author on Google Scholar Find this author on PubMed Search for this author on this site Zan Mitrev 1 Zan Mitrev Clinic; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Goran Kungulovski 2 Fingerprint Diagnostics Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Goran Kungulovski For correspondence: goran.kungulovski{at}zmc.mk Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Mutations in chromatin regulator (CR) genes are frequent across human cancers and have been associated with increased tumor mutational burden (TMB) and improved response to immune checkpoint inhibitor (ICI) treatment. Here, using discovery and independent validation cohorts, we resolved these associations at the level of individual cancer types and investigated whether shared CR mutation patterns emerge across colorectal cancer, melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, bladder cancer, esophagogastric cancer, pancreatic adenocarcinoma, prostate cancer, and breast cancer. For each cancer type, we identified a distinct set of pro-survival CR genes, whose mutations were associated with improved survival following ICI treatment. We further identified a subset of recurrent CRs that were associated with improved ICI outcomes across many cancer types, although the magnitude of the association varied between cancers. Co-occurrence of mutations in two or more CRs was associated with further improvement in survival, while several individual CR genes showed particularly robust associations with favorable ICI outcomes. Across cancer types, CR-altered groups consistently displayed higher TMB than their corresponding CR-unaltered groups. Transcriptomics-based deconvolution further revealed cancer-type-specific differences in the tumor microenvironment associated with CR mutations. Together, these findings demonstrate both cancer-specific and recurrent patterns of CR mutations associated with improved outcomes following ICI treatment and further establish a relationship between CR alterations, increased TMB, and ICI response. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Not applicable. This study used exclusively publicly available, de-identified data obtained from previously published cancer genomics datasets and projects; therefore, no additional ethics approval or informed consent was required. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data analyzed in this study are publicly available through the cBioPortal for Cancer Genomics, http://www.cbioportal.org and https://genie.cbioportal.org. http://www.cbioportal.org https://genie.cbioportal.org Funder Information Declared No dedicated research funding was received. Personnel salaries were supported by Fingerprint Diagnostics LLC and Zan Mitrev Clinic, while all analyzed data were publicly available. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted September 16, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy Djansel Bukovec , Marija Gjorgjievska , Sara Kocevska , Mia Nikolova , Lina Mirkovikj , Ivan Kungulovski , Zan Mitrev , Goran Kungulovski medRxiv 2026.09.15.26363151; doi: https://doi.org/10.64898/2026.09.15.26363151 Share This Article: Copy Citation Tools Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy Djansel Bukovec , Marija Gjorgjievska , Sara Kocevska , Mia Nikolova , Lina Mirkovikj , Ivan Kungulovski , Zan Mitrev , Goran Kungulovski medRxiv 2026.09.15.26363151; doi: https://doi.org/10.64898/2026.09.15.26363151 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (901) Anesthesia (333) Cardiovascular Medicine (4818) Dentistry and Oral Medicine (479) Dermatology (415) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1629) Epidemiology (15952) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7050) Geriatric Medicine (733) Health Economics (1065) Health Informatics (5051) Health Policy (1435) Health Systems and Quality Improvement (1768) Hematology (585) HIV/AIDS (1344) Infectious Diseases (except HIV/AIDS) (16294) Intensive Care and Critical Care Medicine (1173) Medical Education (668) Medical Ethics (155) Nephrology (724) Neurology (7276) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3610) Ophthalmology (1053) Orthopedics (398) Otolaryngology (457) Pain Medicine (470) Palliative Medicine (139) Pathology (709) Pediatrics (1799) Pharmacology and Therapeutics (737) Primary Care Research (767) Psychiatry and Clinical Psychology (5901) Public and Global Health (9760) Radiology and Imaging (2425) Rehabilitation Medicine and Physical Therapy (1453) Respiratory Medicine (1249) Rheumatology (641) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)
- [Predicting Cancer Immunotherapy Response Using Dynamic CD8+ T Cell Changes — Pan‑Cancer Retrospect](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-a-predictive-model-for-immunotherapy-efficacy-in-cancer-based-on-dynamic.md)
- [Moderna and Merck's mRNA Cancer Vaccine: Inside the Melanoma Trial Breakthrough](https://medichelpline.com/clinical-feed/stat-news-0-stat-inside-moderna-and-merck-s-cancer-vaccine-triumph.md)
- [Radiopharmaceuticals in Cancer: Promise of Targeted Therapy Meets New Safety Concerns](https://medichelpline.com/clinical-feed/stat-news-2-stat-the-promise-of-radiopharmaceuticals-smacks-into-safety-concerns.md)
- [Arginine supplements and immune recognition: mouse study links arginine to improved cancer and vir](https://medichelpline.com/clinical-feed/medical-news-today-0-could-arginine-supplements-help-boost-immune-responses-to-cancer-viruses.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.